Tarcocimab tedromer

DB18937InvestigationalProtein Based Therapies

Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to...

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form
Curator reviewed
Also known as: Immunoglobulin G1 [240-alanine,241-alanine,243-alanine,449-cysteine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 g1-chain), disulfide with human-Mus musculus monoclonal OG1950 k-chain, (232®232'),(235®235')-
Code names: KSI-301 · OG1953

Resolves to

Compound

UNII7HW5CX6OD5CAS2411896-53-0

Targets

P15692VEGFA

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tarcocimab tedromer, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account